BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05804669 (CRN04894 in ACTH-Dependent Cushing’s Syndrome): BVCT ex-ante prediction vs. reported outcome

On 14 Aug 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 3 Jun 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05804669
Drug Name
CRN04894
Drug MoA
oral ACTH MC2R antagonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Endocrine System Diseases
Indication
ACTH-Dependent Cushing’s Syndrome (ADCS)
Human Patients
18
Sponsor
Crinetics Pharmaceuticals
Phase
Phase 1 Phase 2

Prediction of , index 1060

Prospective Prediction
Prediction Index
1060
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
294 days in advance
Readout Data Interpretation
100% Urinary free cortisol level for ADCS.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)
Phase
Phase 1, Phase 2
Status
Active not recruiting
Enrollment
19
Lead sponsor
Crinetics Pharmaceuticals Inc.
Conditions
Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome
Interventions
DRUG: atumelnant
Design
Sequential · None
Primary purpose
Treatment
Start
2023-10-12
Primary completion
2026-10
Completion
2026-10
Primary outcomes
  • Proportion of participants with treatment emergent adverse events (TEAEs) (Up to Day 15)
  • Proportion of participants with adrenal insufficiency (Up to Day 15)
  • Proportion of participants with safety findings determined by laboratory testing (Up to Day 15)
  • Assessment of the maximum observed plasma concentration of CRN04894 (Up to Day 15)
  • Assessment of the time to achieve maximum observed plasma concentration of CRN04894 (Up to Day 15)

NCT05804669 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials